Frontline Osimertinib/Chemotherapy Combination Improves PFS in EGFR-Mutated NSCLC

Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.

Related Keywords

Massachusetts ,United States ,Boston ,Dana Farber Cancer Institute ,Japan ,Osimertinib Tagrisso ,World Health Organization ,Belfer Center ,Lowe Center ,Chen Huang Center ,Harvard Medical School ,International Association ,Lung Cancer ,Thoracic Oncology ,Applied Cancer Science ,Lung Cancers ,Cancer Care ,Chinese Asian ,Non Small Cell Lung Cancer ,Pasia Jänne ,D ,Phd ,Osimertinib Chemotherapy ,International Association For The Study Of Lung Cancer 2023 World Conference On ,